The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...

The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen for patients with newly-diagnosed chronic lymphocytic leukaemia (CLL) in ...

Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 10:00 AM ESTCompany ParticipantsNadim Ahmed - ...

Creating cultures of loving care is not just the right thing to do for staff and patients, it’s a leadership strategy ...

Q4 2025 Earnings Call February 19, 2026 4:30 PM ESTCompany ParticipantsCaitlin Lowie - Vice President of Corporate Communications ...

The US Ambassador to India, Sergio Gor, and the INDOPACOM commander, Admiral Samuel Paparo, visited the Indian Army’s Western ...

The war in Ukraine has lasted longer than most individuals have anticipated and each night there is a twist to it and it ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Far fewer people who could benefit from statins ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...

The long list of side effects marked on the packaging of statins can be a turn-off for those who might benefit from the cholesterol-lowering drugs. But a new study found only a few of those side ...